메뉴 건너뛰기




Volumn 27, Issue 18, 2009, Pages 2896-2897

Interferon alfa in the postsurgical management of high-risk melanoma: Is it worth it?

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; ALPHA INTERFERON;

EID: 67649961709     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.2133     Document Type: Editorial
Times cited : (4)

References (14)
  • 1
    • 0034669656 scopus 로고    scopus 로고
    • Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials
    • Manola J, Atkins M, Ibrahim J, et al: Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782-3793, 2000
    • (2000) J Clin Oncol , vol.18 , pp. 3782-3793
    • Manola, J.1    Atkins, M.2    Ibrahim, J.3
  • 2
    • 0035880957 scopus 로고    scopus 로고
    • Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
    • Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 3622-3634
    • Balch, C.M.1    Soong, S.J.2    Gershenwald, J.E.3
  • 3
    • 0030030347 scopus 로고    scopus 로고
    • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
    • Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 7-17
    • Kirkwood, J.M.1    Strawderman, M.H.2    Ernstoff, M.S.3
  • 4
    • 0034088027 scopus 로고    scopus 로고
    • High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
    • Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000
    • (2000) J Clin Oncol , vol.18 , pp. 2444-2458
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sondak, V.K.3
  • 5
    • 0035339880 scopus 로고    scopus 로고
    • High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
    • Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 2370-2380
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sosman, J.A.3
  • 6
    • 1842533233 scopus 로고    scopus 로고
    • A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
    • Kirkwood JM, Manola J, Ibrahim J, et al: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. Clin Cancer Res 10:1670-1677, 2004
    • (2004) Clin Cancer Res , vol.10 , pp. 1670-1677
    • Kirkwood, J.M.1    Manola, J.2    Ibrahim, J.3
  • 7
    • 46749103710 scopus 로고    scopus 로고
    • Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial
    • Eggermont AM, Suciu S, Santinami M, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 372:117-126, 2008
    • (2008) Lancet , vol.372 , pp. 117-126
    • Eggermont, A.M.1    Suciu, S.2    Santinami, M.3
  • 8
    • 0029739081 scopus 로고    scopus 로고
    • Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study
    • Cole BF, Gelber RD, Kirkwood JM, et al: Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 14:2666-2673, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 2666-2673
    • Cole, B.F.1    Gelber, R.D.2    Kirkwood, J.M.3
  • 9
    • 0035253368 scopus 로고    scopus 로고
    • Patient preferences for adjuvant interferon alfa-2b treatment
    • Kilbridge KL, Weeks JC, Sober AJ, et al: Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 19:812-823, 2001
    • (2001) J Clin Oncol , vol.19 , pp. 812-823
    • Kilbridge, K.L.1    Weeks, J.C.2    Sober, A.J.3
  • 10
    • 0036499079 scopus 로고    scopus 로고
    • Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data
    • Kilbridge KL, Cole BF, Kirkwood JM, et al: Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 20:1311-1318, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 1311-1318
    • Kilbridge, K.L.1    Cole, B.F.2    Kirkwood, J.M.3
  • 11
    • 0036727090 scopus 로고    scopus 로고
    • Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
    • Kirkwood JM, Bender C, Agarwala S, et al: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20:3703-3718, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 3703-3718
    • Kirkwood, J.M.1    Bender, C.2    Agarwala, S.3
  • 12
    • 67649933805 scopus 로고    scopus 로고
    • Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
    • Bottomley A, Coens C, Suciu S, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 27:2916-2923, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 2916-2923
    • Bottomley, A.1    Coens, C.2    Suciu, S.3
  • 13
    • 46949091404 scopus 로고    scopus 로고
    • Adjuvant therapy of melanoma: Is pegylated interferon alfa-2b what we've been waiting for?
    • Sondak VK, Flaherty LE: Adjuvant therapy of melanoma: Is pegylated interferon alfa-2b what we've been waiting for? Lancet 372:89-90, 2008
    • (2008) Lancet , vol.372 , pp. 89-90
    • Sondak, V.K.1    Flaherty, L.E.2
  • 14
    • 32644454916 scopus 로고    scopus 로고
    • Prognostic significance of autoimmunity during treatment of melanoma with interferon
    • Gogas H, Ioannovich J, Dafni U, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718, 2006
    • (2006) N Engl J Med , vol.354 , pp. 709-718
    • Gogas, H.1    Ioannovich, J.2    Dafni, U.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.